Danicamtiv治疗扩张型心肌病的2期开放标签试验
该研究从体外评估到2a期开放标签试验,评估Danicamtiv在MYH7或TTN变异及其他病因扩张型心肌病中的安全性和疗效。41例患者接受口服Danicamtiv治疗,MYH7和TTN队列LVEF较基线改善,其他病因队列改善较小,药物总体耐受良好。
要点
- Danicamtiv在体外增强野生型和DCM相关肌球蛋白活性及心肌纤维力产生。
- MYH7和TTN变异队列LVEF较基线分别改善8.8%和5.9%,其他病因队列改善4.4%。
- 治疗中出现的不良事件均为轻中度,1例停药,3例其他病因患者出现无症状心肌肌钙蛋白升高。
核心结论
- Danicamtiv短期治疗在DCM患者中总体耐受良好,超声心动图结果与药物增强肌球蛋白功能/可用性一致,MYH7和TTN队列收缩功能改善最有利。
研究设计与样本
- 体外评估Danicamtiv对DCM变异心肌肌球蛋白酶活性和左心室纤维力产生的影响。
- 2a期基线对照开放标签试验,按变异(MYH7或TTN)或其他病因将DCM患者纳入队列。
- 治疗期1口服Danicamtiv 25 mg每日两次,治疗期2剂量调整为10或50 mg每日两次。
- 主要终点为安全性/耐受性,次要终点包括超声心动图评估的心脏结构和功能变化。
- 共纳入41例患者,平均年龄49.6±13岁,平均基线LVEF 33.4%±8.0%;MYH7变异12例,TTN变异14例,其他病因15例。
主要发现
- 体外实验中Danicamtiv增加野生型和DCM肌球蛋白活性,并增加心肌纤维力产生。
- 41例中22例(53.7%)报告治疗中出现的不良事件,均为轻中度,1例停药。
- 其他病因队列中3例检测到无症状心肌肌钙蛋白升高。
- 治疗期2后,MYH7队列LVEF较基线改善8.8%(95%CI:5.03%-12.64%)。
- TTN队列LVEF较基线改善5.9%(95%CI:2.59%-9.28%),其他病因队列改善4.4%(95%CI:-0.90%至9.73%)。
临床怎么用
- 对于MYH7或TTN变异相关DCM患者,Danicamtiv可能改善收缩功能,但需进一步随机对照试验验证。
- 治疗期间需监测不良事件,尤其是其他病因患者的心肌肌钙蛋白变化。
局限性
- 本研究为开放标签、基线对照设计,样本量较小(41例),缺乏安慰剂对照。
- 其他病因队列LVEF改善的95%CI跨越无效线。
- 研究期限短,长期安全性和疗效未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision therapies for dilated cardiomyopathy (DCM) are lacking despite diverse manifestations and clinical trajectories based on underlying etiology. DCM-associated pathogenic variants in cardiac beta-myosin heavy chain (MYH7) and titin (TTN) can impair the function/availability of cardiac myosin. Danicamtiv is a novel investigational small molecule that selectively enhances cardiac myosin function. OBJECTIVES: The study sought to translationally evaluate danicamtiv in the setting of myosin dysfunction, from in vitro assessments to a clinical trial exploring its safety and efficacy in DCM due to MYH7 or TTN variants, or other causes (either positive or negative genetic results). METHODS: The danicamtiv effects on DCM-variant cardiac myosin enzyme activity and skinned left ventricular (LV) fiber force generation were assessed in vitro. A phase 2a, baseline-controlled, open-label trial enrolled individuals with DCM into cohorts by variants (MYH7 or TTN) or other causes. In the week of treatment period (TP)1, participants received oral danicamtiv 25 mg twice daily with dose adjustment in TP2 to 10 or 50 mg twice daily. The primary endpoint was safety/tolerability; secondary endpoints included echocardiography-assessed changes in cardiac structure/function. RESULTS: In vitro, danicamtiv increased the activity of wild-type and DCM myosin, increasing force production in cardiac fibers. Forty-one participants were enrolled in the trial (mean age 49.6 ± 13 years; mean baseline LV ejection fraction 33.4% ± 8.0%). Twelve had MYH7 variants, 14 had TTN variants, and 15 had other cause DCM. Treatment-emergent adverse events were reported in 22 (53.7%) of 41 participants (all mild or moderate; 1 discontinuation); an asymptomatic increase in cardiac troponin was detected in 3 participants in the other causes cohort. After TP2, the MYH7 and TTN cohorts showed improvements from baseline in LV ejection fraction (MYH7: 8.8% [95% CI: 5.03%-12.64%]; TTN: 5.9% [95% CI: 2.59%-9.28%]) but less in the other causes cohort (4.4% [95% CI: -0.90% to 9.73%]). CONCLUSIONS: Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with DCM. Echocardiography outcomes were consistent with a danicamtiv-induced enhancement of myosin function/availability; MYH7 and TTN cohorts generally had the most favorable responses in contractile function. (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy Due to Genetic Variants or Other Causalities; NCT04572893).
引用
- Lakdawala NK, Hershberger RE, Garcia-Pavia P, et al. Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial. J Am Coll Cardiol. 2025. PMID: 41217321. doi:10.1016/j.jacc.2025.09.1511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。